In COVID-19 patients, IL-6 levels are significantly elevated, so serum IL-6 was used as a biomarker of COVID-19 severity and to decide on the administration of immunosuppressive treatment for the famous cytokine storm, based on experience in rheumatological and autoimmune diseases. This evidence concerns the gene IL6 and autoimmune disease.